Mike Bromley has over 15 years of experience in medical mycology research. He works on the mechanistic basis of fungal pathogenicity with the translational emphasis of developing novel antifungal agents. Whilst working for F2G Ltd, a University of Manchester spin-out company, Mike made a major contribution to the identification of potential drug targets in A. fumigatusand to advancing these discoveries through target validation to drug development.
His research team discovered and exploited mobilisable genetic elements in A. fumigatus which facilitated discovery of numerous essential genes. Several gene products have subsequently been validated as novel drug target candidates against which Mike and collaborators at F2G Ltd have developed high-throughput inhibitor screens, revealing novel, now patented, inhibitors.
Mikes team has also developed high-throughput gene replacement strategies for A. fumigatus and chemical genetic screens to identify the mechanism of action of antifungal agents. Mike is currently the co-ordinator of a 6.1M FP7 collaborative research program (NOFUN: www.nofunproject.org) taking novel antifungal compounds from hits to clinical trials.